Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEVETEN vs ATACAND
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Hypertension,Treatment of hypertension (alone or in combination with other antihypertensive agents)
Treatment of hypertension,Treatment of heart failure (NYHA class II-IV and left ventricular systolic dysfunction) to reduce cardiovascular death and hospitalization for heart failure
400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
Terminal elimination half-life is approximately 7-8 hours in patients with normal renal function, supporting once-daily dosing.
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Primarily metabolized by glucuronidation (UGT1A3, UGT2B7); minimal CYP450 metabolism.
Candesartan is primarily metabolized by ester hydrolysis to its active metabolite, candesartan, and further undergoes O-deethylation by CYP2C9 (minor route).
Renal (approximately 60% as unchanged drug) and biliary/fecal (approximately 40%).
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Approximately 99% bound to plasma proteins, primarily albumin.
High protein binding: >99%, primarily to serum albumin.
Approximately 0.3 L/kg, indicating distribution mainly in extracellular fluid.
Volume of distribution (Vd) is approximately 0.13 L/kg (mean 9 L). This low Vd indicates limited extravascular distribution, consistent with high plasma protein binding.
Oral: approximately 15-20% due to extensive first-pass metabolism; absorption is not significantly affected by food.
Absolute oral bioavailability is approximately 15% (prodrug candesartan cilexetil is completely converted to active candesartan during absorption). Food does not affect bioavailability.
Cr Cl 30-59 m L/min: no adjustment; Cr Cl <30 m L/min: 200-400 mg once daily; hemodialysis: not studied, use with caution.
No initial dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min (including dialysis), initiate at 4 mg once daily and titrate cautiously with monitoring.
No adjustment required for mild to moderate impairment; not studied in severe impairment (Child-Pugh C).
For Child-Pugh Class A or B: initiate at 4 mg once daily and titrate cautiously. Child-Pugh Class C: not recommended (no data).
Safety and efficacy not established in pediatric patients <18 years.
For children ≥1 year and <6 years: 0.2-0.4 mg/kg/day once daily or divided twice daily; maximum 0.6 mg/kg/day (up to 32 mg/day). For children ≥6 years: 4-8 mg once initially; may increase to 16 mg once daily (or 32 mg daily in larger children).
No specific adjustment needed, but start at lower end of dosing range (400 mg once daily) due to potential renal impairment and increased sensitivity.
Start at 4 mg once daily in patients ≥75 years; adjust based on blood pressure response and renal function (e.g., GFR <30 m L/min).
None
When pregnancy is detected, discontinue ATACAND as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Avoid use in pregnancy (fetal toxicity/neonatal morbidity/mortality),Hypotension in volume-depleted patients (e.g., diuretic therapy, dialysis),Hyperkalemia in patients with renal impairment or potassium-sparing diuretics/supplements,Acute renal failure in patients with bilateral renal artery stenosis or solitary kidney,Monitor renal function and serum potassium periodically
Hypotension: Symptomatic hypotension may occur in volume-depleted patients or those with heart failure.,Hyperkalemia: Monitor serum potassium, especially in patients with renal impairment or on potassium-sparing diuretics.,Renal impairment: Use caution in patients with renal artery stenosis or severe renal impairment; monitor renal function.,Fetal/neonatal morbidity and mortality: As noted in black box warning.,Avoid use in patients with bilateral renal artery stenosis or unilateral stenosis in a solitary kidney.
Concomitant use with aliskiren in patients with diabetes mellitus (type 2) or moderate to severe renal impairment (e GFR <60 m L/min/1.73 m²),Hypersensitivity to eprosartan or any component,Pregnancy (especially second and third trimesters)
Hypersensitivity to candesartan or any component of the formulation,Concomitant use with aliskiren in patients with diabetes
No specific food interactions. Avoid excessive potassium intake (e.g., potassium-rich foods like bananas, oranges, tomatoes, spinach) as TEVETEN may increase serum potassium. No restrictions with alcohol, but limit intake as it may lower blood pressure and increase side effects. Grapefruit juice has no known interaction.
No significant food interactions. Avoid potassium-rich foods (e.g., bananas, oranges, spinach, avocados) in large amounts if also taking potassium supplements or potassium-sparing diuretics. Salt substitutes containing potassium chloride should be used cautiously.
Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure is associated with a low risk of congenital anomalies, but second- and third-trimester exposure is associated with oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal hypotension, anuria, and renal failure. TEVETEN (eprosartan mesylate) is an angiotensin II receptor blocker, and its use is contraindicated in pregnancy, especially during the second and third trimesters.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, skull ossification defects, hypotension, anuria) due to direct renin-angiotensin system blockade. Risk of neonatal renal failure and hypotension if exposed after 20 weeks gestation.
Eprosartan is excreted in rat milk at concentrations approximately 2.4 times higher than maternal plasma. No data exist on its excretion in human breast milk. Due to the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. The M/P ratio in humans is unknown.
No data on candesartan in human milk; animal studies detect drug in milk. M/P ratio unknown. Avoid breastfeeding due to potential risk of neonatal hypotension and renal impairment.
TEVETEN is contraindicated in pregnancy, and no dose adjustments are recommended because the drug should not be used. If pregnancy is detected, discontinue the drug as soon as possible. Pharmacokinetic changes in pregnancy, such as increased plasma volume, may alter the drug's effect, but use is not advised.
Avoid use in second and third trimesters due to fetotoxicity. If inadvertent exposure occurs, discontinue drug immediately. No dose adjustment recommended for first trimester use, but consider alternative antihypertensive agent throughout pregnancy.
TEVETEN (eprosartan mesylate) is an angiotensin II receptor blocker (ARB) with a high affinity for the AT1 receptor. It has a dose-dependent antihypertensive effect. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. Monitor renal function and serum potassium in patients with renal impairment, diabetes, or those on potassium-sparing diuretics. May cause angioedema, though rare. Use with caution in patients with unilateral or bilateral renal artery stenosis due to risk of acute renal failure.
ATACAND (candesartan cilexetil) is an angiotensin II receptor blocker (ARB) used primarily for hypertension and heart failure. Monitor renal function and electrolytes, especially potassium, within 2-4 weeks of initiation or dose adjustment. Avoid use in pregnancy (Category D). May cause angioedema; discontinue immediately if occurs. Dual blockade with ACE inhibitors or aliskiren increases risk of hypotension, hyperkalemia, and renal impairment.
Take TEVETEN exactly as prescribed, usually once daily, with or without food.,Do not stop taking this medication without consulting your doctor, as it may worsen your condition.,Avoid becoming pregnant while on TEVETEN; use effective contraception and inform your doctor immediately if you think you are pregnant.,Report any signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to your doctor immediately.,Inform all healthcare providers that you are taking TEVETEN, especially before surgery or any procedure requiring anesthesia.,Stay hydrated, but do not use potassium supplements or salt substitutes containing potassium without medical advice.,Monitor your blood pressure regularly as directed and keep a log to share with your doctor.
Take ATACAND exactly as prescribed, typically once daily with or without food.,Do not use if pregnant or planning pregnancy; consult doctor immediately if pregnancy occurs.,May cause dizziness or lightheadedness, especially during initial therapy; avoid driving until effects are known.,Avoid potassium supplements or salt substitutes containing potassium unless directed by healthcare provider.,Report signs of angioedema (swelling of face, lips, throat, difficulty breathing) or fainting to physician immediately.,Maintain adequate hydration and avoid dehydration (excessive sweating, vomiting, diarrhea).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEVETEN vs ATACAND, answered by our medical review team.
TEVETEN is a Angiotensin II Receptor Blocker that works by Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.. ATACAND is a Angiotensin II Receptor Blocker that works by Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEVETEN and ATACAND depend on the specific clinical indication. These are both Angiotensin II Receptor Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEVETEN is: 400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.. The standard adult dose of ATACAND is: Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEVETEN and ATACAND in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEVETEN is classified as Category C. Drugs acting directly on the renin-angiotensin system (RAS) can cause fetal and neonatal morbidity and death when used in pregnancy. First-trimester exposure is associated with a l. ATACAND is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Fetal toxicity (oligohydramnios, renal dysfunction, sk. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.